Severe oral mucositis is a major cause of morbidity following allogeneic hematopoietic stem cell transplantation (AHSCT). Cryotherapy, that is, the application of ice chips on the mucosa of the oral cavity during the administration of antineoplastic agents, may reduce the incidence and severity of chemotherapy-related oral mucositis. In this multicenter randomized study, we addressed whether cryotherapy during MTX administration is effective in the prevention of severe oral mucositis in patients undergoing myeloablative AHSCT. One hundred and thirty patients undergoing myeloablative AHSCT and MTX-containing GVHD prophylaxis were enrolled and randomized to receive or not receive cryotherapy during MTX administration. The incidence of severe (grade 3-4) oral mucositis, the primary end point of the study, was comparable in patients receiving or not cryotherapy. Moreover, no difference was observed in the incidence of oral mucositis grade 2-4 and the duration of oral mucositis grade 3-4 or 2-4, or in the kinetics of mucositis over time. In univariate and multivariate analysis, severe oral mucositis correlated with TBI in the conditioning regimen and lack of folinic acid rescue following MTX administration. Thus, cryotherapy during MTX administration does not reduce severe oral mucositis in patients undergoing myeloablative allogeneic HSCT. Future studies will assess cryotherapy before allogeneic HSCT.
Severe oral mucositis is a major cause of morbidity following allogeneic hematopoietic stem cell transplantation (AHSCT). Cryotherapy, that is, the application of ice chips on the mucosa of the oral cavity during the administration of antineoplastic agents, may reduce the incidence and severity of chemotherapy-related oral mucositis. In this multicenter randomized study, we addressed whether cryotherapy during MTX administration is effective in the prevention of severe oral mucositis in patients undergoing myeloablative AHSCT. One hundred and thirty patients undergoing myeloablative AHSCT and MTX-containing GVHD prophylaxis were enrolled and randomized to receive or not receive cryotherapy during MTX administration. The incidence of severe (grade 3-4) oral mucositis, the primary end point of the study, was comparable in patients receiving or not cryotherapy. Moreover, no difference was observed in the incidence of oral mucositis grade 2-4 and the duration of oral mucositis grade 3-4 or 2-4, or in the kinetics of mucositis over time. In univariate and multivariate analysis, severe oral mucositis correlated with TBI in the conditioning regimen and lack of folinic acid rescue following MTX administration. Thus, cryotherapy during MTX administration does not reduce severe oral mucositis in patients undergoing myeloablative allogeneic Introduction Mucositis, an inflammatory condition of the mucosa of the gastrointestinal tract, is a common complication of cytotoxic chemoradiotherapy regimens resulting in damage to epithelial cells. The duration and severity of mucositis is influenced by several factors, including the dose of radiation, and the type and dose of cytotoxic drugs. 1, 2 Mucositis often involves the entire gastrointestinal tract, resulting in erythema, ulceration, pseudomembranes, pain and bleeding. Oral mucositis is the most frequent and debilitating form of mucositis and has been often described by patients as the most distressing complication of highdose therapy. 3 Loss of integrity of the oral mucosa results in a portal of entry for resident microflora, thereby predisposing patients to infection, especially during periods of neutropenia. Therefore, oral mucositis is associated with worse clinical and economic outcomes following anticancer therapy. 4 There is substantial evidence that cryotherapy, that is, the application of ice chips on the mucosa of the oral cavity during the administration of antineoplastic agents, may reduce the incidence and severity of chemotherapy-related oral mucositis. 5 The use of cryotherapy is based on the assumption that ice-induced vasoconstriction will reduce blood flow to the oral mucosa resulting in lower local concentrations of chemotherapeutic agents. 6 Cryotherapy has been shown to reduce the incidence of oral mucositis by 50% following intravenous administration of 5FU (5-fluorouracil). 7, 8 Inhibition of 5FU-induced oral mucositis was achieved when cryotherapy was applied for at least 30-60 min following 5FU infusion. 9 Cryotherapy has been effective also for the prevention of oral mucositis following treatment with high-dose Melphalan and autologous stem cell rescue. [10] [11] [12] There are no randomized studies addressing the effectiveness of cryotherapy in the prevention of oral mucositis following allogeneic hematopoietic stem cell transplantation (AHSCT). Severe oral mucositis occurs in 70-85% patients undergoing myeloablative AHSCT. 5 Although mucositis is mostly caused by high-dose chemotherapyand radiotherapy-containing pretransplant regimens, it has been previously shown that the administration of posttransplant Methotrexate (MTX) for graft-versus-host disease (GVHD) prophylaxis is associated with increased incidence of severe oral mucositis. 13 In a preliminary study performed in our institution, cryotherapy during MTX administration reduced severe oral mucositis by 41 percentage points as compared to a historical control cohort (42 vs 73%, respectively) following myeloablative AHSCT (Gori, personal communication, GITMO Meeting, May 2003). Thus, a multicenter randomized study was designed to address the effectiveness of cryotherapy for the prevention of severe oral mucositis following myeloablative AHSCT.
Patients and methods

Patients
The study was sponsored by the GITMO Nurses Group and coordinated by the Institute of Hematology and Medical Oncology at the University of Bologna. Patient enrollment started on October 1, 2004 and went on until January 31, 2006. One hundred and thirty patients undergoing myeloablative AHSCT and MTX-containing GVHD prophylaxis were enrolled and randomized to receive or not cryotherapy during MTX administration. Enrollment criteria included myeloablative pretransplant conditioning, post transplant GVHD prophylaxis with MTX, age of at least 8 years old and signing of informed consent. Patients with clinical evidence of mucositis at enrollment were excluded, as well as patients who did not receive at least three administrations of MTX following transplant. After giving their informed consent, patients were included in a preformed randomization list that was updated by the coordinating center. Randomization was performed at the ratio of 1 patient per arm with no further stratifications.
MTX pharmacokinetics and ice administration MTX was administered at standard doses (20 mg/sm on day þ 1, 15 mg/sm on days þ 3, þ 6 and þ 11) as an intravenous infusion lasting about 5 min (72). Patients randomized to the cryotherapy group were required to apply the ice preparation to the oral mucosa for at least 1 h starting at the time when MTX was administered. Treatment duration was based on preliminary pharmacokinetic studies, performed in eight patients (not included in the study) receiving an allogeneic HSC transplant at the University of Bologna after a myeloablative-conditioning regimen (five including total body irradiation (TBI)), showing that following each MTX administration, mean MTX concentrations were maximal after 30 min, then rapidly declined, with an estimated half life of 30-60 min ( Figure 1 ). On the basis of these data, we estimated that cryotherapy should last for at least 1 h.
Ice preparations could consist of either ice chips made from mineral water or of commercially purchased popsicles. The patients were instructed to keep the ice inside the mouth until it melted. Fifty patients (41%) received folinic acid as rescue at various doses and schedules, starting 6-24 h following MTX administration. Evaluation of the oral cavity was performed once daily by a nurse, and the severity of oral mucositis was scored based on the WHO scale ( Table 1 ). The study protocol required that oral mucositis be scored for at least 20 days after transplant, or earlier provided the score was 0 for three consecutive days, and up to 30 days if mucositis persisted.
Statistical analysis
The study objective was to evaluate the effectiveness of cryotherapy in the prevention of oral mucositis in patients treated with low-dose MTX as GVHD prophylaxis following myeloablative allogeneic stem cell transplantation. The primary end point of the study was the incidence of severe (grade 3-4) oral mucositis. Secondary end points were the incidence of oral mucositis grade 2-4, the duration of oral mucositis grade 3-4 both in patients with this complication and in the whole cohort (the duration of oral mucositis in patients with a score o3 was arbitrarily defined as 0) and the duration of oral mucositis grade 2-4 both in patients with this complication and in the whole cohort.
The size of the sample was determined based on a previous study, where cryotherapy lowered the incidence of severe oral mucositis by 41 percentage points as compared to a historical control cohort (42 vs 73%, respectively) (Gori, E et al., personal communication, GITMO meeting, May 2003), with a t-test 90% power and a two-sided significance level of 0.05. Each patient was assigned a daily score of oral mucositis. For purposes of analysis, a maximal score of oral mucositis was attributed to each patient. Incidence of oral mucositis was compared between the two groups by means of w 2 test. For measurement of duration, patients whose oral mucositis did not resolve at day 30 were attributed a duration of 30 days. Duration of oral mucositis was compared by means of Wilcoxon rank-sum test.
The following factors were analyzed as independent variables in univariate analysis for their correlation with mucositis grade 3-4 as a dependent variable: cryotherapy, gender, age, a TBI-containing preparatory regimen, donor type, stem-cell source, number of MTX administrations and the use of folinic acid rescue. Categorical variables were correlated by the means of Kruskal-Wallis test. Continuous variables, such as age, were correlated by the means of ANOVA test. Factors that correlated with grade 3-4 mucositis with a P-value of p0.1 were included in the multivariate analysis. The multivariate analysis was performed by logistic regression analysis. All statistical analysis were performed with SPSS software version 12.0.
Results
One hundred and thirty patients were enrolled. Eight patients were excluded following enrollment and/or randomization because they did not meet the inclusion criteria: one patient because the center did not send enrollment sheet, one because of early death, two because they received a reduced intensity conditioning regimen, four because they received less than three doses of MTX post transplant. One hundred and twenty-two patients, 62 in the cryotherapy group and 60 in the control group, were then evaluable for analysis. Patient characteristics are described in Table 2 . Patients in the cryotherapy and control group were comparable for demographic and transplant-related factors, although there was a trend toward a older age in the control group, that included also less patients o14 years old (2 vs 5). Moreover, patients given cryotherapy were more likely to have received their transplants from unrelated donors than control patients. As shown in Table 3 , the incidence of severe (grade 3-4) oral mucositis was comparable in the two groups, with only a slight not significant decrease in patients receiving cryotherapy. Six patients enrolled in the cryotherapy arm did not actually complete cryotherapy as planned because of refusal or poor tolerance. However, the exclusion of these patients did not change the results (the incidence of severe oral mucositis in the patients receiving ice chips was 26 out of 56, 46.4%, P ¼ 0.45). Moreover, no difference was observed in the incidence of grade 2-4 mucositis, as shown in Table 3 .
Cryotherapy did not significantly change the kinetics of the mucositis score over time, as shown in Figure 2 . Both groups reached a maximum mucositis score at the same time (11 vs 12 days) . Moreover, the maximum mean mucositis score was comparable (1.9871.12 in cryotherapy patients vs 2.1371.24 in control patients, P ¼ 0.56).
Duration of mucositis was then compared between the two groups. Duration of mucositis among patients with either grade 3-4 or grade 2-4 mucositis was comparable in the two groups (Table 3 ). The same was true when the duration of grade 3-4 mucositis was calculated for all patients, by arbitrarily defining the duration of oral mucositis in patients with a score o3 as 0 days (median duration of 0 days, range 0-19 in the cryotherapy group, as compared to 3 days, range 0-23 in the control group, P ¼ 0.8).
Finally, the correlation between grade 3-4 mucositis and the variables listed in Table 4 was analyzed in the entire cohort. As shown in Table 4 , in univariate analysis grade 3-4 mucositis was significantly associated with TBI-based conditioning regimens and with the lack of folinic acid rescue following MTX administration. As above, ice administration, as well as gender, donor type, graft source and number of MTX doses, did not correlate with grade 3-4 mucositis. In multivariate analysis, both TBI-based conditioning and lack of folinic acid rescue correlated with severe oral mucositis (RR ¼ 3.2 and 2.6, respectively, P ¼ 0.007 and 0.015). However, in a subset analysis, cryotherapy did not affect the incidence of severe oral mucositis either in patients receiving TBI (73.6 vs 64.7% in control patients, P ¼ 0.55) or in patients not receiving folinic acid (54.2 vs 70.2%, P ¼ 0.16), thus ruling out a potential confounding effect of these factors.
Discussion
This multicenter-randomized study explored the role of cryotherapy in the prevention of severe oral mucositis in patients receiving MTX-based GVHD prophylaxis following myeloablative allogeneic HSCT. One hundred and thirty patients were enrolled, to our knowledge the largest cohort to be prospectively studied for the effect of The results of our study do not confirm previous observations that cryotherapy is effective in the prevention of severe oral mucositis following both standard and high-dose chemoradiotherapy. 7, 8, 10, 12 The reasons for this discrepancy are presently unknown, but may relate to multiple factors, including the mode of administration, the design of the study, or the biological effect of posttransplant low-dose MTX in the pathogenesis of oral mucositis. In our study, ice chips were applied for 60 min, based on preliminary data from our group showing that bolus intravenous administration of MTX leads to peak plasma levels within 30 min in HSCT patients (Figure 1) . Moreover, in previous reports of patients receiving cryotherapy following standard dose chemotherapy with 5FU, 9 it was shown that increasing further the time of application did not lead to greater protection. However, cryotherapy following high-dose chemotherapy with or without radiotherapy has been usually performed for longer times, up to 6 h. 10 Moreover, MTX elimination half-life can increase to much longer times in patients with impaired renal and hepatic failure.
14 Finally, cellular clearance of MTX by-products, including MTX-polyglutamates, may require up to 2 weeks and contribute to delayed toxicity.
14,15 Therefore, reducing mucosal blood flow during MTX peak plasma concentrations may not be sufficient to prevent MTX-dependent late toxic effects.
Therefore, we cannot exclude that increasing the time of exposure of the oral mucosa to ice chips will improve the protective effect of cryotherapy on oral mucositis. Another potential reason of the lack of effect of cryotherapy may be the unexpectedly low rate of severe mucositis in our control group as compared to other studies on mucositis following high-dose therapy (70-100%) 16 and allogeneic HSCT.
Finally, it is possible that preventing MTX toxicity may not have a significant impact on the risk of severe oral mucositis following myeloablative allogeneic HSCT. The role of MTX in determining mucositis following allogeneic myeloablative transplantation is still a matter of debate. Post-transplant GVHD prophylaxis with MTX has been shown to increase the risk of severe oral mucositis as compared with non-MTX-containing prophylaxis regimens. 13 This is further supported by the observation that patients receiving folinic acid rescue may have a lower incidence of severe oral mucositis (Table 4) . However, the use of folinic acid rescue in association with MTX for GVHD prophylaxis following allogeneic HSCT is not established. In our study, eight out of 14 centers employed folinic acid rescue with various doses and schedules. Folinic acid rescue has been associated with reduced severe oral mucositis in patients receiving MTX-containing GVHD prophylaxis regimens in most but not all studies. 17, 18 Although there is concern that folinic acid supplementation may reduce the effectiveness of MTX and therefore increase GVHD, 19 this has not been observed in most studies, suggesting a possible role of folinic acid rescue in the prevention of MTX-induced oral mucositis following allogeneic HSCT.
In conclusion, our study suggests that cryotherapy, as applied here, does not have a significant role in the prevention of mucositis in patients receiving MTX-containing GVHD prophylaxis following HSCT. However, in view of the major role of pre-transplant radio/chemotherapy in determining severe oral mucositis, cryotherapy might be employed to prevent oral damage during conditioning, particularly in association with drugs known to be associated previously with mucosal damage, such as Melphalan and Busulfan. This has been shown to be effective in patients receiving high-dose Melphalan before autologous transplantation. 10 Moreover, it should be tested whether cryotherapy might synergize with new drugs such as Palifermin, 20 in the prevention of severe oral mucositis following allogeneic myeloablative HSCT.
